fig1

Figure 1. The exRNA LYPLAL1-DT is upregulated in SCLC patients and internalized by SCLC cells. (A) The expression level of LYPLAL1-DT in serum exosomes of SCLC patients and normal controls; (B) Exosomes were confirmed by electron microscopy (scale bar: 50 nm); (C) NTA analysis of exosomes; (D) Detection of exosome markers by Western blotting; (E) Detection of LYPLAL1-DT in exosomes secreted by LYPLAL1-DT–OE and OC H446 cells; (F) Internalization of PKH67-labeled exosomes assessed by fluorescence microscopy (scale bar: 50 and 10 μm); (G) Internalization of PKH67-labeled exosomes assessed by flow cytometry. Data are presented as mean ± SD. Differences between the two groups were analyzed by Student’s t-test, whereas comparisons among more than two groups were analyzed by one-way ANOVA. (^*P < 0.05; ^**P < 0.01; ^***P < 0.001; ^****P < 0.0001). exRNA: Extracellular RNA; LYPLAL1-DT: LYPLAL1 divergent transcript; SCLC: small cell lung cancer; NTA: nanoparticle tracking analysis; OE: overexpression; OC: overexpression control; SD: standard deviation; ANOVA: analysis of variance; PKH67: PKH67 green fluorescent cell linker.